Safe Orthopaedics announces the publication of a biomechanical study on Sycamore
08 Agosto 2023 - 1:00AM
Safe Orthopaedics announces
the publication of a biomechanical
study on Sycamore
- Publication in the
Journal of Experimental Orthopaedics of the results of the Sycamore
biomechanical study
- Over 160 patients
treated with Sycamore
|
|
|
|
Éragny-sur-Oise,
Fleurieux sur
l’Arbresle, France, le 07
août 2023 à 17h30 CET – Safe
(FR001400F1V2 – ALSAF), french group specialized in the design,
manufacturing and distribution of ready-to-use medical devices for
Spine surgeries, especially safe for vertebral fracture treated in
emergency, announces the publication of a biomechanical study of
Sycamore and over 160 patients treated with Sycamore.
Publication of
the
results
of the Sycamore
biomechanical
study in the
Journal of Experimental Orthopaedics
(https://jeo-esska.springeropen.com/articles/10.1186/s40634-023-00635-7)
Leaded by Professor Jean-Charles Le Huec, the
study compares the biomechanical behavior of vertebrae treated by
“Dowelplasty”, a new surgical technique using a pedicle anchored
device Sycamore (commercial name by Safe Orthopedics) with a
traditional kyphoplasty system. The study is published in the
Journal of Experimental Orthopedics.
Sycamore consists of (a) a cannulated titanium
nail and (b) a titanium dowel directly anchored in the pedicle; (c)
the cannulated nail is inserted and locked into the dowel, and the
cement is injected through the nail.
Results:
In comparison with the Kyphoplasty, Sycamore
shows a significant increase of the compression strength (373
N ; IC à 95% ; – 331 N versus – 1076 N for Sycamore).
Conclusions:
1- The treatment of a compression fracture with Sycamore allows
a very significant increase in the resistance to load of the
fractures compared to the pre-treatment state.
2 - Sycamore provides a greater improvement in
load resistance and fracture displacement energy than balloon
kyphoplasty, suggesting that Sycamore may be a good alternative for
the treatment of vertebral compression fractures.
Sycamore provides greater improvement of the
load resistance and fracture displacement energy compared to
traditional kyphoplasty, suggesting that Sycamore is a good
alternative for the treatment of vertebrae compression
fractures.
Professor Jean-Charles Le Huec, user of the
system confirms in clinical practice the good results obtained in
the laboratory. With a follow-up of 2 years, the losses of
corrections do not exceed 2.1° compared to the immediate
postoperative results. This is truly remarkable compared to
kyphoplasty and other systems on the market without pedicle
anchorage where the cement can sink into the vertebral body,
especially in cases of osteoporosis.
Pierre Dumouchel, Chairman and CEO de Safe Group
comments « First of all, we would like to thank Professor
Jean-Charles Le Huec and all the surgeons who contributed to the
development and clinical follow-up of Sycamore, a unique and
patented Safe Orthopedics technology for better management of
patients with vertebral fractures. We have treated over 160
patients with our Sycamore technologies and are seeing very
promising clinical results. Through recent listings in many French
centers and international deployment, we are delighted to be able
to benefit a large number of patients from the clinical benefits
already observed and aim to accelerate the Safe Orthopaedics
sales».
About Safe Group
Safe Group is a French medical technology group
that brings together Safe Orthopaedics, a pioneer in ready-to-use
technologies for spine pathologies, and Safe Medical (formerly LCI
Medical), a medical device subcontractor for orthopedic surgeries.
The group employs approximately 125 people.
Safe Orthopaedics develops and manufactures kits combining
sterile implants and ready-to-use instruments, available at any
time to the surgeon. These technologies are part of a minimally
invasive approach aimed at reducing the risks of contamination and
infection, in the interest of the patient and with a positive
impact on hospitalization times and costs. Protected by 15 patent
families, SteriSpineTM kits are CE marked and FDA approved. Safe
Orthopaedics is headquartered in the Paris region (95610
Eragny-sur-Oise) and has subsidiaries in the United Kingdom,
Germany, the United States, and the Lyon region
(Fleurieux-sur-l'Arbresle).
For more information: http://www.safeorthopaedics.com/
Safe Medical produces implantable medical devices and
ready-to-use instruments. It has an innovation center and two
production sites in France (Fleurieux-sur-l'Arbresle, 69210) and in
Tunisia, offering numerous industrial services: industrialization,
machining, finishing and sterile packaging.
For more information: http://www.safemedical.fr/
Contacts Safe
Group François-Henri
Reynaud
Chief
Financial and Administrative Officer
Tél.
: +33 (0)1 34 21 50
00 investors@safeorthopaedics.com
SAFE (EU:ALSAF)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
SAFE (EU:ALSAF)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025